The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.

Back

ESC Professional Premium Access

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.

Session: Real-world evidence on the cardiovascular effects of therapies for diabetes

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor S. Maragkoudakis (Chania, GR)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Spyridon Maragkoudakis

General Hospital St. George, Chania (Greece)

0 follower

8 more presentations in this session

Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis

Speaker: Mr B. Tan (Singapore, SG)

The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK biobank

Speaker: Doctor T. Guo (Xi'an, CN)

All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries

Speaker: Doctor P. Yazdanfard (Hilleroed, DK)

Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report.

Speaker: Doctor M. Feola (Mondovi, IT)

Identification and optimisation of a risk stratified cohort of patients with type 2 diabetes through the delivery of a enhanced pharmacist-led service

Speaker: Mr S. Mcbrien (Belfast, GB)

Access the full session

Real-world evidence on the cardiovascular effects of therapies for diabetes

Speakers: Doctor S. Maragkoudakis, Mr B. Tan, Doctor T. Guo, Doctor P. Yazdanfard, Doctor M. Feola...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources